Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures.
Options
BORIS DOI
Date of Publication
November 21, 2023
Publication Type
Article
Division/Institute
Contributor
Martí, Yasmina | |
Batson, Sarah | |
Mitchell, Stephen | |
Gorni, Ksenija | |
Gusset, Nicole | |
Oskoui, Maryam | |
Servais, Laurent | |
Sutherland, C Simone |
Series
Neurology
ISSN or ISBN (if monograph)
0028-3878
Publisher
Lippincott Williams & Wilkins
Language
English
Publisher DOI
PubMed ID
37813581
Description
BACKGROUND AND OBJECTIVES
Spinal muscular atrophy (SMA) is a progressive neuromuscular disorder associated with continuous motor function loss and complications such as scoliosis and contractures. Understanding the natural history of SMA is key to demonstrating the long-term outcomes of SMA treatments. This study reviews the natural history of motor function, scoliosis, and contractures in patients with SMA.
METHODS
Electronic databases were searched from inception to June 27, 2022 (Embase, MEDLINE, and Evidence-Based Medicine Reviews). Observational studies, case-control studies, cross-sectional studies, and case series reporting on motor function (i.e., sitting, standing, and walking ability), scoliosis, and contracture outcomes in patients with Types 1-3 SMA were included. Data on study design, baseline characteristics, and treatment outcomes were extracted. Datasets were generated from studies that reported Kaplan-Meier (KM) curves and pooled to generate overall KM curves.
RESULTS
Ninety-three publications were included, of which 68 reported on motor function. Of these, 10 reported KM curves (three on the probability of sitting in patients with Types 2 and 3 SMA, and eight on the probability of walking/ambulation in patients with Type 3 SMA). The median time to loss of sitting (95% confidence interval [CI]) was 14.5 years (14.1-31.5) for the Type 2 SMA sitter population (their maximum ability was independent sitting). The median time to loss of ambulation (95% CI) was 13.4 years (12.5-14.5) for Type 3a SMA (disease onset at age <3 years) and 44.2 years (43.0-49.4) for Type 3b SMA (disease onset at age ≥3 years). Studies including scoliosis and contracture outcomes mostly reported non-time-to-event data.
DISCUSSION
Results demonstrate that a high degree of motor function loss is inevitable, affecting patients of all ages. Additionally, data suggest that untreated patients with Types 2 and 3 SMA remain at risk of losing motor milestones during late adulthood, and patients with Types 3a and 3b SMA are at risk of loss of ambulation over time. These findings support the importance of stabilization of motor function development even at older ages. Natural history data are key for the evaluation of SMA treatments as they contextualize the assessment of long-term outcomes.
Spinal muscular atrophy (SMA) is a progressive neuromuscular disorder associated with continuous motor function loss and complications such as scoliosis and contractures. Understanding the natural history of SMA is key to demonstrating the long-term outcomes of SMA treatments. This study reviews the natural history of motor function, scoliosis, and contractures in patients with SMA.
METHODS
Electronic databases were searched from inception to June 27, 2022 (Embase, MEDLINE, and Evidence-Based Medicine Reviews). Observational studies, case-control studies, cross-sectional studies, and case series reporting on motor function (i.e., sitting, standing, and walking ability), scoliosis, and contracture outcomes in patients with Types 1-3 SMA were included. Data on study design, baseline characteristics, and treatment outcomes were extracted. Datasets were generated from studies that reported Kaplan-Meier (KM) curves and pooled to generate overall KM curves.
RESULTS
Ninety-three publications were included, of which 68 reported on motor function. Of these, 10 reported KM curves (three on the probability of sitting in patients with Types 2 and 3 SMA, and eight on the probability of walking/ambulation in patients with Type 3 SMA). The median time to loss of sitting (95% confidence interval [CI]) was 14.5 years (14.1-31.5) for the Type 2 SMA sitter population (their maximum ability was independent sitting). The median time to loss of ambulation (95% CI) was 13.4 years (12.5-14.5) for Type 3a SMA (disease onset at age <3 years) and 44.2 years (43.0-49.4) for Type 3b SMA (disease onset at age ≥3 years). Studies including scoliosis and contracture outcomes mostly reported non-time-to-event data.
DISCUSSION
Results demonstrate that a high degree of motor function loss is inevitable, affecting patients of all ages. Additionally, data suggest that untreated patients with Types 2 and 3 SMA remain at risk of losing motor milestones during late adulthood, and patients with Types 3a and 3b SMA are at risk of loss of ambulation over time. These findings support the importance of stabilization of motor function development even at older ages. Natural history data are key for the evaluation of SMA treatments as they contextualize the assessment of long-term outcomes.
File(s)